{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:42:56Z","timestamp":1777902176944,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eclinm.2025.103750","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:44:04Z","timestamp":1767901444000},"page":"103750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Temporal trends in progression risk in smoldering myeloma: a systematic review"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.eclinm.2025.103750_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103750_bib2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103750_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.seminoncol.2022.01.007","article-title":"Modern radiographic imaging in multiple myeloma, what is the minimum requirement?","volume":"49","author":"Mena","year":"2022","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103750_bib4","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103750_bib5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103750_bib6","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103750_bib7","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103750_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41408-024-01170-z","article-title":"Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database","volume":"14","author":"Rajkumar","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103750_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.61","article-title":"Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma","volume":"8","author":"Mellgard","year":"2024","journal-title":"Hemasphere"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103750_bib10","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103750_bib11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D'Arena","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103750_bib12","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3390\/curroncol28030188","article-title":"Testing Mayo clinic's new 20\/20\/20 risk model in another cohort of smoldering Myeloma patients: a retrospective study","volume":"28","author":"Tessier","year":"2021","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103750_bib13","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103750_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.eclinm.2025.103750_bib15","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1182\/bloodadvances.2025016083","article-title":"Patterns of progression among 427 Smoldering Myeloma patients diagnosed after 2014: importance of monitoring","volume":"9","author":"Kastritis","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103750_bib16","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103750_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103750_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.76","article-title":"The evolving pattern of the monoclonal protein improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma","volume":"8","author":"de Daniel","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.eclinm.2025.103750_bib20","article-title":"Smoldering myeloma after IMWG update: factors predictive of evolution, role of advanced imaging, and of clinical judgment. A real life retrospective experience","volume":"2","author":"Torti L Ma","year":"2018","journal-title":"Hemasphere"},{"issue":"282","key":"10.1016\/j.eclinm.2025.103750_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103750_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/bimj.201900056","article-title":"Generalized parametric cure models for relative survival","volume":"62","author":"Jakobsen","year":"2020","journal-title":"Biom J"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103750_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Base Ment Health"},{"key":"10.1016\/j.eclinm.2025.103750_bib24","series-title":"Identifying and quantifying heterogeneity","first-page":"107","author":"Borenstein","year":"2009"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103750_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study","volume":"97","author":"S\u00f8rrig","year":"2016","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103750_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41408-021-00569-2","article-title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103750_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103750_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2911.2911","article-title":"Over 30% of smoldering myeloma patients have tumor cell bone marrow infiltration patterns similar to multiple myeloma: a large (n=544) clinical study using whole-body MRI","volume":"120","author":"Hillengass","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103750_bib29","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103750_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02771","article-title":"Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance","author":"Mateos","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103750_bib31","article-title":"Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests","volume":"363","author":"O'Sullivan","year":"2018","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103750_bib32","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","author":"Kristinsson","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103750_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.100","article-title":"Prevalence, incidence and survival of smoldering multiple myeloma in the United States","volume":"6","author":"Ravindran","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103750_bib34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103750_bib35","series-title":"World Population Prospects 2024: Summary of Results","author":"Nations","year":"2024"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103750_bib36","first-page":"8","article-title":"A century of primary transformation, chapter 2: rise of the specialists","volume":"100","author":"Bendix","year":"2023","journal-title":"Med Econ J"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103750_bib37","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103750_bib38","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","article-title":"Genomic landscape of multiple myeloma and its precursor conditions","volume":"57","author":"Alberge","year":"2025","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103750_bib39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-023-00919-2","article-title":"Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma","volume":"13","author":"Liu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103750_bib40","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.4081\/hr.2020.9054","article-title":"The molecular pathogenesis of multiple myeloma","volume":"12","author":"Bolli","year":"2020","journal-title":"Hematol Rep"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103750_bib41","article-title":"Smoldering multiple myeloma: impact of the evolving pattern on early progression","volume":"124","author":"De Larrea","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103750_bib42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103750_bib43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosi\u00f1ol","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103750_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Hematol"},{"key":"10.1016\/j.eclinm.2025.103750_bib45","article-title":"Enhanced risk stratification of smoldering multiple myeloma with dynamic biomarkers: a multinational, multicenter study including 2,270 participants (PANGEA 2.0)","author":"Chabrun","year":"2025","journal-title":"Res Sq"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103750_bib46","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","article-title":"Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma","volume":"28","author":"Termini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2025.103750_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2024-202676","article-title":"Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma","volume":"144","author":"Nadeem","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2025.103750_bib48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II plattform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103750_bib49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41408-024-01159-8","article-title":"Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma","volume":"14","author":"Werly","year":"2024","journal-title":"Blood Cancer J"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103750_bib50","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.2024023880","article-title":"Smoldering multiple myeloma: taking the narrow over the wide path?","volume":"143","author":"Avet-Loiseau","year":"2024","journal-title":"Blood"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:22:09Z","timestamp":1777634529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025006856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["S2589537025006856"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103750","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal trends in progression risk in smoldering myeloma: a systematic review","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103750"}}